Regeneron Pharmaceuticals's results for Q3 2026 (quarter ended Sep 30, 2026) come from the company's own earnings release, filed with the SEC on 2026-10-30. Everything below is taken from that filing; quotes are copied exactly. Company outlooks are the company's own.
At a glance
| Item | Value |
|---|---|
| Revenue (GAAP) | $5,116 million (+36.3% vs a year earlier) |
| Diluted EPS (GAAP) | $18.45 |
| Adjusted per-share figure (company's non-GAAP measure; FFO/AFFO for REITs) | $20.07 |
| Full-year guidance | Stated (no change given) |
Guidance
Regeneron gives no 2026 revenue or EPS guidance; it updated expense, gross margin, capex and tax-rate ranges, with higher R&D and lower SG&A.
Why this label: No revenue/EPS guidance; prior vs updated table moves only R&D, SG&A, gross margin, capex and tax lines (non-core), so not 'mixed'.
| Metric | Period | New | Prior (as stated in the release) |
|---|---|---|---|
| GAAP R&D | FY2026 | $6.600–6.735 billion | $6.500–6.635 billion |
| non-GAAP R&D | FY2026 | $6.050–6.150 billion | $5.950–6.050 billion |
| GAAP SG&A | FY2026 | $2.730–2.860 billion | $2.830–2.960 billion |
| non-GAAP SG&A | FY2026 | $2.400–2.500 billion | $2.500–2.600 billion |
| GAAP gross margin on net product sales | FY2026 | approximately 80% | 78%–79% |
| non-GAAP gross margin on net product sales | FY2026 | approximately 86% | 84%–85% |
| GAAP cost of collaboration and contract manufacturing (COCM) | FY2026 | $985 million–$1.035 billion (unchanged) | $985 million–$1.035 billion |
| capital expenditures | FY2026 | $1.050–1.100 billion | $1.030–1.100 billion |
| GAAP effective tax rate | FY2026 | approximately 14% | 13%–14% |
| non-GAAP effective tax rate | FY2026 | approximately 15% | 14%–15% |
From the release
Revenue: "Total revenues · $ · 5,116 · $ · 3,754 · 36 · %"
Earnings per share: "GAAP EPS increased 35% to $18.45; non-GAAP EPS (a) increased 70% to $20.07"
GAAP R&D: "GAAP R&D · $6.500–$6.635 billion · $6.600–$6.735 billion"
non-GAAP R&D: "Non-GAAP R&D (a) · $5.950–$6.050 billion · $6.050–$6.150 billion"
GAAP SG&A: "GAAP SG&A · $2.830–$2.960 billion · $2.730–$2.860 billion"
Quotes are copied from the filing; in table rows, cell borders are shown as “·”.
Key fact: Q3 total revenues rose 36% to $5.1 billion; non-GAAP EPS up 70% to $20.07.
Source
Regeneron Pharmaceuticals earnings release (SEC filing), accession 0000872589-26-000032, filed 2026-10-30.
Part of the Q3 2026 Guidance Tracker. Educational only, not advice. Free weekly recap every Sunday: yieldterminalpro.com/newsletter.